Public Trial Protocol Disclosures Negate “Half-Truth” Liability for Safety-Event Statements in Securities Fraud Claims

1. Introduction

In Re: Apellis Pharmaceuticals, Inc. Securities Litigation is a putative class action appeal in which purchasers of Apellis stock alleged violations of Exchange Act §§ 10(b) and 20(a) and SEC Rule 10b-5. The plaintiffs targeted statements made during the class period (January 28, 2021 to July 28, 2023) asserting that no cases of retinal vasculitis were observed in Apellis’s Phase III clinical trials (OAKS and DERBY) for pegcetacoplan, later FDA-approved and marketed as SYFOVRE for geographic atrophy.

After post-approval reports of retinal vasculitis and a stock decline, plaintiffs contended Apellis’s trial-related statements were actionable half-truths: even if literally true (no observed cases), they allegedly misled investors by omitting that the trials were “not designed” to detect retinal vasculitis—principally because the protocols did not mandate prompt fluorescein angiography follow-ups in certain clinical situations (e.g., inflammation, ischemic neuropathy, or early post-dropout timing).

The district court dismissed on two independent grounds—(1) no materially misleading statement/omission and (2) no adequate scienter allegations. The First Circuit affirmed on the first ground alone, expressly declining to reach scienter.

2. Summary of the Opinion

The First Circuit held the challenged statements were not actionable half-truths because the supposedly omitted “critical qualifying information” was not actually withheld: the timing and circumstances of fluorescein angiography were fully disclosed through publicly available trial protocols (FDA-approved and posted on ClinicalTrials.gov) and were followed. Fluorescein angiography is the most common accepted test for detecting retinal vasculitis, was required at specified intervals, and clinicians could order it as warranted. No retinal vasculitis was detected during the trials or in prior pegcetacoplan testing. With no contradiction and no concealed material fact, plaintiffs failed to plead a material misrepresentation or omission. The dismissal was affirmed.

3. Analysis

3.1. Precedents Cited

Premca Extra Income Fund LP v. Angle

The court relied on Premca Extra Income Fund LP v. Angle for two foundational points: (i) what materials can be considered at the motion-to-dismiss stage (well-pleaded allegations plus undisputed authentic documents, official public records, and documents sufficiently referenced), and (ii) the elements of a plausible § 10(b) claim, including the requirement of a material misrepresentation or omission. This framework allowed the panel to treat the publicly available trial protocols as properly considered context when evaluating whether an omission theory was plausible.

Macquarie Infrastructure Corp. v. Moab Partners, L.P. (quoting Universal Health Servs., Inc. v. United States ex rel. Escobar)

The core doctrinal lens came from Macquarie Infrastructure Corp. v. Moab Partners, L.P., which defined half-truths as statements that “state the truth only so far as it goes, while omitting critical qualifying information,” quoting Universal Health Servs., Inc. v. United States ex rel. Escobar. The First Circuit treated this as the operative test: liability turns on whether the omitted information is “critical” and “qualifying,” such that its absence makes the affirmative statement misleading in context.

SEC v. Lemelson

Plaintiffs invoked SEC v. Lemelson to show that even “technically true” statements can be actionable if they mislead by omission. The First Circuit distinguished Lemelson: there, the speaker said a company did not intend to conduct clinical trials while omitting that it planned to hire a third party to conduct them—creating a misleading impression through a factual contradiction (the stated implication versus the undisclosed plan). In Apellis, by contrast, the court found no comparable contradiction because the protocols did include fluorescein angiography (the recognized detection method) and the “no cases observed” statement aligned with what the protocol-driven testing revealed.

SEC v. Johnston

Similarly, SEC v. Johnston was distinguished. In Johnston, an executive said there had been no “formal discussions” with the FDA about a second trial and he could not speculate, while omitting that the FDA had recommended a second trial. That omission created a misleading impression about the regulatory posture. In Apellis, the panel concluded there was no undisclosed regulatory recommendation or hidden contrary fact; the asserted omission was essentially a criticism of protocol choices that were already available to investors.

Lafortune v. Garland

While not central to the merits, Lafortune v. Garland supported the court’s procedural choice to bypass a potential forfeiture dispute and decide the plaintiffs’ “study design” argument on the merits—reflecting a pragmatic appellate approach when the claim fails regardless.

3.2. Legal Reasoning

The opinion’s reasoning proceeds in a tight sequence:

  1. Reframe the alleged “design omission” into concrete asserted missing facts. The court treated the plaintiffs’ “not designed to detect vasculitis” theory as hinging on two specific alleged omissions: (a) the protocols left to clinicians whether to order fluorescein angiograms upon inflammation/ischemic neuropathy rather than requiring them in all such cases; and (b) the protocols did not require fluorescein angiograms for dropouts until 30+ days after exit.
  2. Ask whether those “omissions” were actually undisclosed. The court held they were not: Apellis had “full and complete disclosures” of when fluorescein angiograms would be given, via publicly available protocols (FDA-approved and posted on ClinicalTrials.gov). Thus, the market “knew what the defendants were doing and the outcomes arising from those actions.”
  3. Reject “half-truth” characterization absent withheld qualifying information. Because the protocols described the testing schedule and discretion, the defendants did not omit “critical qualifying information” within the meaning of Macquarie Infrastructure Corp. v. Moab Partners, L.P..
  4. Emphasize alignment—not contradiction—between statement and disclosed testing method. The defendants’ statements (no observed vasculitis) did not clash with the fact that fluorescein angiography—the accepted test—was used at specified times and could be used as clinically indicated.
  5. Decline to reach scienter. Having concluded no actionable misrepresentation/omission was pled, the court affirmed without deciding whether plaintiffs adequately alleged scienter.

3.3. Impact

The decision is likely to influence securities-fraud pleading and defense strategy in life-sciences cases in several ways:

  • Public protocol disclosure as a powerful “no-omission” defense. Where trial protocols and testing schedules are publicly available and incorporated into the market’s information set, plaintiffs will face a higher hurdle in reframing methodological critiques as actionable omissions.
  • Limits on “not designed to detect” theories. Plaintiffs often attempt to convert adverse-event surprises into claims that earlier “no signal” statements were misleading because the study “wasn’t designed” to find them. This opinion indicates such theories falter when the disclosed protocol includes recognized detection tools and the alleged “missing” qualifiers are inferable from, or contained in, the protocol itself.
  • Half-truth liability remains, but requires genuine concealment. The court reaffirmed the viability of half-truth claims (consistent with SEC v. Lemelson and SEC v. Johnston) while sharpening the boundary: half-truths require undisclosed, critical qualifying facts—not merely dissatisfaction with disclosed scientific choices.
  • Investor sophistication is contextual. The court noted it did not foreclose that, in another case, scientific detail could be so complex that plain-English statements might mislead despite technical public documents. That caveat leaves room for future plaintiffs where disclosures are truly opaque or incomplete, but signals that courts will scrutinize what, in fact, was available to the market.

4. Complex Concepts Simplified

  • Section 10(b) / Rule 10b-5: Anti-fraud provisions that prohibit materially misleading statements or deceptive omissions in connection with buying or selling securities.
  • Material misrepresentation or omission: A statement that is false or misleading, or a failure to disclose information necessary to make what was said not misleading, where the information would matter to a reasonable investor.
  • Half-truth: A statement that is literally true but misleading because it leaves out a crucial qualifier that changes the statement’s overall meaning in context (as framed by Macquarie Infrastructure Corp. v. Moab Partners, L.P.).
  • Scienter: The required culpable mental state in many securities-fraud claims—typically intent to deceive or a high degree of recklessness. (Not decided on appeal here.)
  • Motion to dismiss (Rule 12(b)(6)): A request to end the case at the pleading stage because, even if the complaint’s factual allegations are assumed true, the law does not provide a remedy on those facts.
  • Clinical trial protocol: The detailed plan for how a study is run—what tests are administered, when, and under what conditions. Here, the protocol’s public availability was decisive because it supplied the “qualifiers” plaintiffs said were missing.

5. Conclusion

The First Circuit’s affirmance in In Re: Apellis Pharmaceuticals, Inc. Securities Litigation crystallizes a practical rule for securities-fraud claims premised on clinical-trial safety statements: a “no cases observed” assertion is not an actionable half-truth where the allegedly missing qualifiers about testing frequency and triggers are already disclosed through publicly available protocols that were followed, especially when the protocols employ recognized detection methods and no contradictory facts are concealed. The opinion preserves half-truth doctrine (as in SEC v. Lemelson and SEC v. Johnston) but confines it to cases involving genuine nondisclosure of critical qualifying information—not post hoc disputes about disclosed scientific methodology.